Revenue segments as reported by the company.

Premiums

Product revenue

Administrative fees and other revenue

Net investment income

Net gains on financial instruments

Gain on sale of business

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit expense

Selling, general and administrative

Interest expense

Amortization of other intangible assets

Loss on extinguishment of debt

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Elevance Health Inc

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. The firm supports consumers, families, and communities across the entire care journey, connecting them to the care, support, and resources they need to lead healthier lives. It offers health plans and clinical, behavioral, pharmacy, and complex-care solutions which promote whole health. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elevance Health reports robust Q4 earnings, eyes margin optimization

Elevance Health's strong Q4 2022 performance, strategic acquisitions, and focus on margin optimization position the company for continued growth. With a clear outlook for 2023, emphasizing membership expansion and margin recovery, the company is poised for success. Challenges in optimizing margins and managing cost structures are balanced by growth opportunities and strategic initiatives.

Elevance Health reports robust Q1 growth and innovation in healthcare

Elevance Health Inc demonstrated strong financial performance and growth in Q1 2023, driven by increased membership and solid operating results.
The company's focus on advocacy, innovation, and sustainability, along with strategic investments in healthcare capabilities, positions it for continued success.
While facing challenges in cost management and strategic partnerships, Elevance Health is well-positioned to capitalize on opportunities in specialty care and value-based models.
Overall, Elevance Health's commitment to whole health, innovation, and value-based care sets a positive trajectory for future growth and industry leadership.

Elevance Health Inc posts robust Q2 earnings, eyes value-based care

Elevance Health Inc reported strong Q2 earnings, raised adjusted EPS outlook to over $32.85 for the year, and emphasized a focus on value-based care and digital solutions. While facing margin pressure in Carelon, the company remains confident in its strategy execution and performance for 2023 and beyond.

Elevance Health excels in Q3, eyes growth through strategic actions

Elevance Health's Q3 performance was strong, with a focus on operational efficiency and strategic investments. Challenges in Medicare ratings were addressed through proactive measures, while opportunities lie in growth acceleration and strategic partnerships. The company remains on track to achieve its long-term growth targets.

Elevance Health Inc surpasses earnings expectations, eyes growth opportunities

Elevance Health Inc's strong financial performance in Q4 2023 and full-year results, coupled with strategic initiatives in expanding capabilities and enhancing operational efficiency, position the company for continued success. Challenges in commercial repricing and Medicaid dynamics are being addressed, while opportunities in Medicare Advantage and strategic investments offer avenues for growth.

Elevance Health posts robust Q1 earnings, eyes strategic growth

Elevance Health demonstrated strong financial performance in Q1, with revenue growth and margin expansion in key segments.
While facing challenges like potential Medicare rate cuts, the company is leveraging partnerships and acquisitions for growth.
Opportunities lie in expanding service offerings, geographic footprint, and optimizing Medicaid margins for long-term sustainability.

Elevance Health Inc reports robust earnings growth and strategic wins

Elevance Health's Q2 performance reflects strong earnings growth and reaffirmed guidance, driven by solid segment performance and new business wins.
The company's strengths lie in its high Medicare rating, robust revenue growth in services, and strategic focus on value creation.
Challenges include sustaining growth momentum, managing funding cuts, and effectively integrating recent acquisitions for long-term success.
Opportunities exist in accelerating capabilities, expanding market share, optimizing operations, and leveraging workplace recognition for talent attraction and innovation.

Elevance Health faces Medicaid challenges, sees growth in AI investments

Elevance Health's Q3 earnings were impacted by elevated medical costs in Medicaid, leading to a reduction in full-year outlook. Despite challenges in the Medicaid business, the company's Medicare Advantage and Commercial businesses are performing well. Investments in AI and expansion of Carelon Services present growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance. The Government Business segment includes medicare and medicaid businesses, national government services, and services provided to the federal government. The CerelonRx segment offers formulary management, pharmacy networks, prescription drug database, member services, and mail order capabilities. The Other segment is involved in health services business focused on quality of healthcare by enabling and creating new care delivery and payment models. The company was founded in 1944 and is headquartered in Indianapolis, IN.

ELV is reallocating resources to more profitable areas and making prudent acquisitions.

Elevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?

Becton, Dickinson and Co.

LyondellBasell Industries

Rogers Communications

Rexford Industrial Realty

Investing in blue-chip stocks at 52-week lows can potentially yield significant returns if fundamentals are strong. Avoid value traps by focusing on companies with solid fundamentals, like Elevance Health, Becton, Dickinson, LyondellBasell, Rogers Communications and Rexford Industrial Realty. These companies offer a 3.7% yield and a 27% discount to fair value, and they have historically outperformed the market with 27% less volatility.

Santa's Stunning Stocking Surprises: 5 High Yield Blue-Chip Bargains For 2025

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Elevance Health Inc. (NASDAQ: ELV) to determine whether certain Elevance officers and directors violated securities laws and breached fiduciary duties to shareholders. Elevance is a healthcare company that supports consumers, families, and communities across the entire care journey.

Robbins LLP Informs Elevance Health Inc. Stockholders that it is Investigating the Officers and Directors of ELV to Determine if They Breached Fiduciary Duties Owed to Shareholders

Cigna

CVS Health

UnitedHealth Group

Centene

Humana

Shares of major healthcare companies fell nearly 5% on Wednesday on concerns related to potential changes to their complex business models. That includes UnitedHealth Group, Cigna and CVS Health, which operate three of the nation's largest private health insurers and drug supply chain middlemen called pharmacy benefit managers.

Health care stocks fall as lawmakers, patients push for changes to their business models

Shares of health insurers such as UnitedHealth and CVS Health fell on Wednesday after a Wall Street Journal report said a bipartisan group of lawmakers were set to introduce legislation to break up pharmacy-benefit managers.

Health insurer stocks fall as WSJ says lawmakers set to break up pharmacy-benefit managers

Elevance Health has shown robust financial performance, with a 9.1% revenue CAGR and 13.7% EPS growth over the past decade. Despite recent share price weakness, ELV's long-term fundamentals remain strong, presenting an investment opportunity. ELV's valuation is attractive, with a forward PE of 11.2x, lower than its 10-year average, and potential upside driven by AI integration.

Elevance Health: A Quality Underpriced Stock Returning To Health

Avanos Medical Inc

Atlanta Braves Holdings Inc

AVNS, BATRK and ELV have been added to the Zacks Rank #5 (Strong Sell) List on December 11, 2024.

New Strong Sell Stocks for December 11th

Thompson's death sparked a wide social media conversation over frustrations with navigating the US health insurance system.

UnitedHealth, rival insurer stocks continue to tumble after Brian Thompson's murder in NYC

Shares of health insurance companies including UnitedHealth Group continued to fall on Friday, two days after Brian Thompson, the CEO of the company's health insurance unit, was fatally shot outside a Manhattan hotel by a gunman lying in wait.

Health insurer shares fall after UnitedHealth exec murder

Shares of UnitedHealthcare's parent company led a broader selloff in health insurance stocks, losses one analyst described as a likely result of the industry's fresh focus following the Wednesday killing of UnitedHealthcare's chief executive Brian Thompson.

Health Insurance Stocks—Led By UnitedHealth—Suffer Steep Drops Following Brian Thompson's Killing

When Anthem Blue Cross Blue Shield said it will no longer pay for anesthesia care if the surgery or procedure exceeds an arbitrary time limit, parent company Elevance Health Inc ELV faced backlash and reneged on the policy change.

Elevance Health Stock Falls As Anthem Faces Backlash Over Anesthesia Policy, Announces Reversal

SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Elevance Health, Inc. (NYSE: ELV) or any of its executive officers violated securities laws by misrepresenting or failing to timely disclose material information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Elevance Health, Inc. Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

Accenture Plc

Amphenol

Canadian National Railway Company

Domino's Pizza

Global Payments

Intuit

Lam Research

Monolithic Power Systems

MSCI

Nordson

ResMed

Rollins

SPDR S&P 500 ETF Trust

Vanguard Dividend Appreciation ETF

Zoetis

The SPDR S&P 500 ETF Trust posted a strong gain of 5.96% in November, resuming its strong run in 2024. The Top 15 dividend growth stocks for December 2024 offer an average dividend yield of 1.2% and appear to be about 22% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 12.41% compound annual growth rate.

My Top 15 High-Growth Dividend Stocks For December 2024

Elevance Health, Inc. (NYSE:ELV ) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET Company Participants Mark Kaye - Executive VP & CFO Conference Call Participants A.J. Rice - UBS A.J.

Elevance Health, Inc. (ELV) UBS Global Healthcare Conference (Transcript)

ELV encounters headwinds such as higher benefit costs, an increased debt level and member attrition in the Medicaid business, which raise concerns among investors.

Elevance Health Declines 20% in 3 Months: Time to Sell the Stock?

Molina Healthcare

Several US health insurers saw notable stock price gains following the reelection of former US President Donald Trump amid an expectation of less federal scrutiny. Humana Inc. experienced the largest increase as its stock rose 10.7% from Nov. 1 through Nov. 6, increasing from $260.71 a share to $288.51 a share.

Trump Win Gives Some U.S. Health Insurers A Post-Election Bump On Wall Street

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Elevance Health, Inc. (NYSE: ELV) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Elevance Health, Inc. Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) announced today that senior management is scheduled to present at the UBS Global Healthcare Conference in Rancho Palos Verdes, California on November 12, at 7:15 a.m. Pacific Standard Time (PST) / 10:15 a.m. Eastern Standard Time (EST). All interested parties are invited to listen to a live webcast of the presentation by visiting www.elevancehealth.com and selecting the “Investors” link. You may also access the link here. For those unab.

Elevance Health Announces Appearance at UBS Global Healthcare Conference

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Ka.

Elevance Health Appoints Nathan Rich Vice President, Investor Relations

Mastercard

Microchip Technology

The SPDR S&P 500 ETF Trust posted a loss of 0.89% in October, putting a pause on its strong run in 2024. The Top 15 dividend growth stocks for November 2024 offer an average dividend yield of 1.24% and appear to be about 23% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved an 11.33% compound annual growth rate.

My Top 15 High-Growth Dividend Stocks For November 2024

Align Technology

A. O. Smith

Enphase Energy

Erie Indemnity

First Solar

Genuine Parts

Mohawk Industries

Moderna

Qorvo

Super Micro Computer

Teradyne

Super Micro joined the list after a 33% drop on Wednesday.

These are the S&P 500's biggest laggards for October, down by as much as 29%

INDIANAPOLIS--(BUSINESS WIRE)-- #maternalhealth--The Elevance Health Foundation, the philanthropic arm of Elevance Health, today announces professional football player Ryan Kelly as its latest Elevance Health Champion. Designed to help increase awareness for critical health challenges and raise funds for local organizations that are making a healthy difference in their communities, the Elevance Health Champion program recognizes professional athletes and organizations who have dedicated their life to leading hea.

Elevance Health Foundation Names Professional Football Player Ryan Kelly as Next Elevance Health Champion

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has assigned a Long-Term Issue Credit Rating of “bbb+” (Good) to Elevance Health, Inc.'s (Elevance Health) (Indianapolis, IN) newly issued $350 million, 4.5% senior unsecured bonds, due 2026; $750 million, 4.750% senior unsecured bonds, due 2030; $750 million, 4.95% senior unsecured bonds, due 2031; $1.2 billion, 5.2% senior unsecured bonds, due 2035; $1.35 billion, 5.7% senior unsecured bonds, due 2055; and $800 million, 5.85% senior unsecured bonds, due.

AM Best Assigns Issue Credit Ratings to Elevance Health, Inc. New Senior Unsecured Bonds

Elevance Health (NYSE: ELV) recently reported its Q3 results, with revenues exceeding but earnings missing the consensus estimates. The company reported revenue of $44.7 billion and adjusted earnings of $8.37 per share, compared to the street estimates of $43.5 billion and $9.66, respectively.

What's Behind The 15% Fall For Elevance Health Stock?

Elevance Health's Q3 2024 results were disappointing with a significant increase in the benefit expense ratio and lowered earnings expectations for the full year. I take a close look at ELV's exposure to government plans and their profitability. I explain why I view Elevance stock as favorably valued even under very conservative near and long-term growth assumptions.

News for Elevance Health Inc Stock (ELV)